CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. §1.10

by certify that this correspondence (along with any paper referred to as being attached or enclosed) is being mailed via "Express Mail Post Office to Addressee" service of the United States Postal Services (Express Mail Label No. EL 754073708 US) on the date shown below in an envelope addressed to the Commissioner for Patents, United States Patent and Trademark Office, Box Sequence Listing, Washington, D.C. 20231.

Dated: February 28, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Atty Docket No.: 018813-0278799

Madison, et. al.

Group Art Unit: 1652

Application No. 09/657,986

Examiner: M. A. Walicka

Filed: September 8, 2000

Title: INHIBITORS OF SERINE PROTEASE ACTIVITY OF MATRIPTASE

TEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §1.821-1.825 TEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §1.821-1.825 TECHCENTER 1600/200 STATEMENT TO SUPPORT FILING AND SUBMISSION

Commissioner for Patents **Box Sequence Listing** Washington, D.C. 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c), (e), (f) and (g), or § 1.825(d) and (b), respectively, are the same.

Respectfully submitted,

Pillsbury Winthrop LLP

By: < SUZANNE L. BIGGS,

Registration No. 30,158

PILLSBURY WINTHROP, LLP 50 Fremont Street P.O. Box 7880 San Francisco, CA 94105-2228 Telephone: (858) 509-4095

Facsimile: (858) 509-4010° Ref. No.: 018813/027 8779 Date: February 28, 2002

| Application/Control Number: 09/657,986 | Page 3 |
|--|--|
| Art Unit: 1652 | |
| NUCLEOTIDE SEQUENCE AND/OR AMI | ence disclosure contained in this application for such a disclosure as set forth in |
| 1. This application clearly fails to complete Applicant's attention is directed to and at 55 FR 18230, May 1, 1990. 2. This application does not contangly sequence Listing as required by 3 and a copy of the Sequence Listing required by 37 C.F.R. 1.821(e). 4. A copy of the Sequence Listing the content of the computer reada 37 C.F.R. 1.822 and/or 1.823, as indicangly sequence Listing. 5. The computer readable form the damaged and/or unreadable as incomputer readable form must be substitute computer readable form must be substituted to substitute computer readable form the substitute computer readable | comply with the requirements of 37 C.F.R. 1.821-1.825. these regulations, published at 1114 OG 29, May 15, 1990 in, as a separate part of the disclosure on paper copy, a 67 C.F.R. 1.821(c). in computer readable form has not been submitted as in computer readable form has been submitted. However, ble form does not comply with the requirements of ated on the attached copy of the marked -up Raw at has been filed with this application has been found to be dicated on the attached CRF Diskette Problem Report. A st be submitted as required by 37 C.F.R. 1.825(d). e Listing is not the same as the computer readable from of |
| An initial or substitute paper copy of directing its entry into the specifical A statement that the content of the where applicable, include no new results. 1.821(g) or 1.825(b) or 1.825(d). | eadable form (CRF) copy of the Sequence Listing. of the Sequence Listing, as well as an amendment ition. a paper and computer readable copies are the same and, matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or |
| For Rules Interpretation, call (703) For CRF Submission Help, call (703) For Patent software help, call (703) | 3) 308-4216 703) 308-4212 |

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE